The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate

Journal of Ocular Pharmacology and Therapeutics

Volumn 14, Issue 6, 1998, Pages 533-542

  Abelson, Mark ^a,b   Howes, John ^c,d   George, Michelle ^a  

^a Ophthalmic Research Associates   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c Pharmos Corporation   (United States)

^d Precision Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LOTEPREDNOL ETABONATE;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYE DISEASE; EYE INFLAMMATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PROVOCATION TEST; PRURITUS; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0031700446     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1998.14.533     Document Type: Article

References (16)

1. Abelson, M.B., George, M.A. and Garofalo, C. Differential diagnosis of ocular allergic disorders Ann. Allergy 70:95-109, 1993.
2. Abelson, M.B., Chambers, W.A. and Smith, L.M. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol. 108:84-88, 1990.
3. Abelson, M.B., Paradis, A., George, M.A., Smith, L.M., Maguire, L. and Burns, R. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol 108:520-524, 1990.
4. Zuber, P. and Pecoud, A. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. J. Allergy Clin. Immunol. 82:590-594, 1988.
5. Rimas, M., Kjellman, N.I., Blychert, L.O and Bjorksten, B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 45:18-21, 1990.
6. Abelson, M., Smith, L., and George, M. A double-masked paired comparison study of the effect of levocabastine and cromolyn sodium 4% on the signs and symptoms of allergic conjunctivitis induced by ocular allergen challenge. Immunol. Allergy Pract. 15:212-213, 1993.
7. Abelson, M.B., George, M.A. and Smith, L.M. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 102:310-316, 1995.
8. Bodor, N. Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Advances Drug Res. 13:255-331, 1984.
9. Bodor, N. Soft drugs: principles and methods for the design of safe drugs. Med. Res. Rev. 4:449-469, 1984.
10. Dell, S.J., Shulman, D.G., Lowry, G.M. and Loteprednol Allergic Conjunctivitis Study Group. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate (LE) in the treatment of seasonal allergic conjunctivitis (SAC). Am. J. Ophthalmol. 123:791-797, 1997.
11. Friedlaender, M.H. and Howes, J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am. J. Ophthalmol. 123:455-464, 1997.
12. Asbell, P.A. and Howes, J. and Loteprednol GPC Study Group II. A double-masked placebo-controlled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of contact-lens associated giant papillary conjunctivitis. CLAO. J 23:31-36, 1997.
13. The Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. Ophthalmology (1998) (in press).
14. Neumann, R. and Howes, J. Loteprednol etabonate: a novel ocular steroid with improved safety profile. In Advances in ocular immunology: Proceedings of the 6th international symposium on the immunology and immunopathology of the eye. R.B. Nussenblatt et al., eds., Bethesda, MD, 1994, pp. 245-248.
15. Bartlett, J.D., Horwitz, B., Laibovitz, R. and Howes, J.F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol. 9:157-165, 1993.
16. Novack, G.D. and Howes, J. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite PJ-91 following chronic ocular administration. J. Ocul. Pharmacol. Ther. 14:153-158, 1998.